Linical and Accelovance have recently merged to create a mid-sized, global CRO with a significant footprint across North America, Europe and Asia-Pacific.
As the next step in the merger, Accelovance has incorporated Linical into its name and will operate as Linical Accelovance Group, which includes Linical Accelovance America, Europe, Romania and China. Additionally, Vita M. Lanoce, has been appointed as CEO of Linical Accelovance Group.
Lanoce, previously COO at Accelovance, has more than 22 years of experience in clinical research at companies including Covance, Synexus (formerly Radiant Research) and Bristol-Myers Squibb. In her new role, Lanoce will oversee all business activities for the Linical Accelovance Group.
“The name change is the next step for us to work collaboratively under a shared vision of quality, success, innovation and communication,” said Lanoce. “I look forward to ensuring the continued delivery of robust solutions and personal service, and guiding our collective strengths for enhanced service offerings.”
Comprising approximately 925 people across more than 20 countries, Linical offers the same reach and experience as larger CROs, yet maintains a personalised, hands-on service approach. The new combined company is capable of conducting studies from early-phase research through large-scale, multinational and late-phase trials.
As a one-stop provider for clinical development programmes, Linical offers a full scope of flexible solutions and a wide range of therapeutic expertise with specialisations in dermatology, immunology, neurology, oncology and vaccines. Linical also demonstrates its oncology expertise through its HERO Project, which combines its scientific expertise and site networks to accelerate oncology therapeutics to market.
Additionally, Linical’s patient engagement solutions are clinical research-focused, enhancing patient recruitment, retention, compliance, surveillance and safety data collection.
